Literature DB >> 2785219

Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations.

J N Kabalin1, J E McNeal, H M Price, F S Freiha, T A Stamey.   

Abstract

Cystoprostatectomy specimens were evaluated in 66 male patients operated on for a pathological condition of the bladder with no evidence of prostatic malignancy on preoperative clinical assessment. There were 38 prostate cancers identified in 25 of 66 patients (38 per cent). Multiple foci of adenocarcinoma were noted in 10 of 25 patients (40 per cent). The mean tumor volume was 0.11 cc, with half of the cancers being less than or equal to 0.01 cc in volume. All 38 cancers were completely localized to the prostate and exact anatomical sites of origin for each of the cancers within the prostate were mapped. Whereas anatomical distribution of the cancers in the anteroposterior dimension was roughly uniform, a distinct predominance of apical prostatic cancers was observed. Possible anatomical explanations and implications of these findings in terms of the apical surgical margins at radical prostatectomy and cystoprostatectomy, and the new technologies currently available for diagnosis of prostate cancer are discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2785219     DOI: 10.1016/s0022-5347(17)41178-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Is sparing the prostate still considered radical cystectomy? The case against prostate-sparing cystectomy for bladder cancer.

Authors:  Ahmed Kotb; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 2.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

3.  Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens.

Authors:  H M Fritsche; A Aziz; F Eder; W Otto; S Denzinger; W F Wieland; M May; F Hofstädter; A Hartmann; M Burger
Journal:  Virchows Arch       Date:  2012-10-09       Impact factor: 4.064

4.  Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.

Authors:  R F Hoedemaeker; J B Rietbergen; R Kranse; T H van der Kwast; F H Schröder
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  Prostate cancer screening (United States).

Authors:  J W Waterbor; A J Bueschen
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

6.  Bladder cancer following prostate cancer--an analysis of risk factors.

Authors:  H E Wegner; T Meier; R Klän; K P Dieckmann
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

7.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  "Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer.

Authors:  Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood
Journal:  Gland Surg       Date:  2018-04

9.  The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.

Authors:  Gabriel P Haas; Nicolas Delongchamps; Otis W Brawley; Ching Y Wang; Gustavo de la Roza
Journal:  Can J Urol       Date:  2008-02       Impact factor: 1.344

Review 10.  Screening for prostate cancer.

Authors:  M L Cher; P R Carroll
Journal:  West J Med       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.